search

Active clinical trials for "Triple Negative Breast Neoplasms"

Results 711-720 of 775

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative...

Triple Negative Breast Cancer

The purpose of this study is to evaluate the efficacy and safety of apatinib in patient with TNBC

Unknown status32 enrollment criteria

Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Triple Negative Breast Neoplasms

This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).

Unknown status35 enrollment criteria

A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases....

Breast Cancer

The study is being conducted to assess the effectiveness and safety of treatment options for breast cancer brain metastases based on molecular typing.

Unknown status31 enrollment criteria

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced...

Triple Negative Breast CancerNab-paclitaxel

This is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% of breast cancer cases and tends to occur in younger women and have biologically more aggressive high grade disease. The purpose of this study is to assess the efficacy and safety of the following two combinations: i) nab-paclitaxel+carboplatin; ii) nab-paclitaxel+capecitabine in subjects with advanced TNBC and up to one prior line of systemic treatment for metastatic disease. Maintenance therapy with capecitabine after completion of combination chemotherapy.

Unknown status22 enrollment criteria

A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

Triple-negative Breast Cancer

HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety and preliminary efficacy of HX008+cisplatin+gemcitabine for the treatment of patients with metastatic triple-negative breast cancer will be evaluated.

Unknown status36 enrollment criteria

A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative...

Triple-negative Breast Cancer

This is a prospective, single-arm and open-label phase II study, evaluating the efficacy and safety of anlotinib combined with tislelizumab and AT regimen as neoadjuvant treatment for triple-negative breast cancer. Participants will undergo/receive PDL1 testing after enrollment. All patients will be receive 6 cycles of low-dose anlotinib combined with tislelizumab and AT(Doxorubicin or Epirubicin+albumin-bound paclitaxel)regimen, followed by surgery.

Unknown status35 enrollment criteria

The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer...

Breast CancerBreast Diseases1 more

This study will look at effects the combination of palbociclib and dose-dense neoadjuvant chemotherapy may have on triple negative breast cancer tumours which have not yet been treated.

Unknown status11 enrollment criteria

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With...

Triple-negative Breast Cancer

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer

Unknown status25 enrollment criteria

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive...

Triple Negative Breast CancerEarly-stage Breast Cancer1 more

An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Neratinib Followed by Weekly Paclitaxel and Carboplatin Plus Neratinib in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)

Unknown status77 enrollment criteria

A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast...

Triple Negative Breast Cancer (TNBC)

The purpose of this study is to evaluate the efficacy and safety of PD-L1 inhibitorin in combination with Anlotinib treatment for patients with triple receptor negative breast cancer treated after failure of standard therapy (including Anthracyclines and/or Taxanes).

Unknown status16 enrollment criteria
1...717273...78

Need Help? Contact our team!


We'll reach out to this number within 24 hrs